Whole-Blood 32-Gene Profiling for Plasma Cell Dyscrasia Detection
Solution Overview
Problem
Current methods for detecting and monitoring plasma cell dyscrasias like multiple myeloma lack sensitivity and specificity, particularly in identifying minimal residual disease and predicting therapeutic responses, and require invasive bone marrow aspirates for gene expression analysis.
Innovation Solution
A 32-gene expression tool that analyzes whole blood samples to detect plasma cell dyscrasias, differentiating between stable and progressive disease, and predicting therapeutic responses using a predictive algorithm.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If bone marrow aspirates are used for gene expression analysis, then diagnostic accuracy can be improved, but patient discomfort and invasiveness increase
Solution Approach 1:
The patent uses circulating plasma cells in peripheral blood as an intermediary substitute for bone marrow aspirates. These circulating cells serve as a mediator that provides the same diagnostic information about plasma cell dyscrasias without requiring invasive bone marrow procedures. The method detects and analyzes these circulating cells through gene expression profiling to achieve accurate diagnosis while avoiding patient discomfort associated with bone marrow aspiration.
2Ease of operation
If standard blood-based biomarkers are used for monitoring, then ease of operation is improved, but sensitivity and specificity for detecting minimal residual disease deteriorate
Solution Approach 1:
The patent changes the parameter being measured from standard blood-based biomarkers (such as protein levels) to gene expression parameters of circulating plasma cells. This parameter change enables the detection of minimal residual disease with high sensitivity while maintaining the ease of using peripheral blood samples. The gene expression profile of circulating plasma cells provides more specific and sensitive information about disease status compared to traditional biomarkers.
Data Source
AI summary
The present invention is directed to methods for detecting a plasma cell dyscrasia like myeloma or MGUS, methods for determining whether a plasma cell dyscrasiais stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a plasma cell dyscrasia to a therapy.